Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Passage Bio stock | $9.17

Learn how to easily invest in Passage Bio stock.

Passage Bio Inc is a biotechnology business based in the US. Passage Bio shares (PASG) are listed on the NASDAQ and all prices are listed in US Dollars. Passage Bio employs 74 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Passage Bio

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PASG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Passage Bio stock price (NASDAQ: PASG)

Use our graph to track the performance of PASG stocks over time.

Passage Bio shares at a glance

Information last updated 2021-10-17.
Latest market close$9.17
52-week range$9.10 - $30.14
50-day moving average $10.63
200-day moving average $13.39
Wall St. target price$28.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.15

Buy Passage Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Passage Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Passage Bio price performance over time

Historical closes compared with the close of $9.17 from 2021-10-20

1 week (2021-10-14) -9.12%
1 month (2021-09-21) -17.54%
3 months (2021-07-21) -29.79%
6 months (2021-04-21) -46.96%
1 year (2020-10-21) -48.10%
2 years (2019-10-17) N/A
3 years (2018-10-17) N/A
5 years (2016-10-17) N/A

Passage Bio financials

Gross profit TTM $0
Return on assets TTM -22.41%
Return on equity TTM -40.43%
Profit margin 0%
Book value $7.46
Market capitalisation $527.4 million

TTM: trailing 12 months

Shorting Passage Bio shares

There are currently 2.9 million Passage Bio shares held short by investors – that's known as Passage Bio's "short interest". This figure is 16.3% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Passage Bio shares can be evaluated.

Passage Bio's "short interest ratio" (SIR)

Passage Bio's "short interest ratio" (SIR) is the quantity of Passage Bio shares currently shorted divided by the average quantity of Passage Bio shares traded daily (recently around 295636.01220753). Passage Bio's SIR currently stands at 9.83. In other words for every 100,000 Passage Bio shares traded daily on the market, roughly 9830 shares are currently held short.

However Passage Bio's short interest can also be evaluated against the total number of Passage Bio shares, or, against the total number of tradable Passage Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Passage Bio's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Passage Bio shares in existence, roughly 50 shares are currently held short) or 0.0934% of the tradable shares (for every 100,000 tradable Passage Bio shares, roughly 93 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Passage Bio.

Find out more about how you can short Passage Bio stock.

Passage Bio share dividends

We're not expecting Passage Bio to pay a dividend over the next 12 months.

Passage Bio overview

Passage Bio, Inc. , a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (ß-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. .

Frequently asked questions

What percentage of Passage Bio is owned by insiders or institutions?
Currently 12.388% of Passage Bio shares are held by insiders and 82.756% by institutions.
How many people work for Passage Bio?
Latest data suggests 74 work at Passage Bio.
When does the fiscal year end for Passage Bio?
Passage Bio's fiscal year ends in December.
Where is Passage Bio based?
Passage Bio's address is: Two Commerce Square, Philadelphia, PA, United States, 19103
What is Passage Bio's ISIN number?
Passage Bio's international securities identification number is: US7027121000
What is Passage Bio's CUSIP number?
Passage Bio's Committee on Uniform Securities Identification Procedures number is: 702712100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site